Genetic biomarkers for PD-1/PD-L1 blockade therapy

@inproceedings{Kataoka2016GeneticBF,
  title={Genetic biomarkers for PD-1/PD-L1 blockade therapy},
  author={Keisuke Kataoka and Seishi Ogawa},
  booktitle={Oncoscience},
  year={2016}
}
Immune checkpoint blockade therapy using antibodies against programmed cell death 1 (PD-1) and PD-1 ligand 1 (PD-L1) is revolutionizing cancer treatment (1-3). These antibodies provide long-term durable responses for patients with various types of advanced cancers, such as melanoma, non–small-cell lung cancer, kidney cancer, and Hodgkin lymphoma (1-3… CONTINUE READING